Virtu Financial’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Virtu Financial’s Portfolio RETA Stock Details RETA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-20,815	Closed	-$682K	–	2264
2022 Q1	$682K	Buy	+20,815	New	+$618K	0.05%	301
2021 Q3	–	Sell	-2,459	Closed	-$348K	–	2135
2021 Q2	$348K	Buy	+2,459	New	+$278K	0.03%	643
2019 Q4	$1.15M	Sell	5,634 -1,451	-20%	-$265K	0.11%	195
2019 Q3	$569K	Buy	+7,085	New	+$601K	0.04%	468
2019 Q2	–	Sell	-6,591	Closed	-$563K	–	1979
2019 Q1	$563K	Buy	+6,591	New	+$547K	0.03%	505

Other funds holding RETA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Virtu Financial's RETA Position: Q2 2022 in Review

Virtu Financial sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q2 2022, closing a stake of 20,815 shares — an estimated $682K sold.

Virtu Financial first reported a position in RETA in Q1 2019 and held it in 5 quarters. The position peaked at $1.15M in Q4 2019. 146 funds tracked by Wall St. Rank hold RETA as of Q2 2022.

Virtu Financial reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q2 2022 after selling out during the quarter.
Virtu Financial sold 20,815 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q2 2022, an estimated $682K.
Virtu Financial first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q1 2019 and held it in 5 quarters.
Virtu Financial's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $1.15M in Q4 2019.
146 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q2 2022.

Based on Virtu Financial's 13F filing for Q2 2022, filed 9 Aug 2022.